InvestorsHub Logo
Followers 11
Posts 25
Boards Moderated 0
Alias Born 11/18/2018

Re: None

Monday, 07/15/2024 1:28:35 AM

Monday, July 15, 2024 1:28:35 AM

Post# of 428445

I have completed an analysis of Amarin, but since Seeking Alpha prohibits the use of AI, which I used only for minor language enhancements, I am seeking alternative platforms to publish my work. Where would you recommend submitting such an analysis?
Here is a short summary of this analysis:
• Mineral oil toxicity can be refuted (see Chapter 2, 3, 4).
• The differences in omega-3 formulations between REDUCE-IT and STRENGTH account for the latter's failure and invalidate any attempts to extrapolate its findings to the former (see Chapter 5).
• The JAMA Cardiology paper (see Annex 12) supporting the STRENGTH investigators' case is riddled with biases (see Chapter 6).
Immediate Actions for Amarin
Request for the Retraction of the JAMA Cardiology Article’ s Discussion, a crucial step in restoring confidence in Vazkepa.
Considers Legal Actions Against Unsupported Public Statements against Vazkepa:
Counters Superficially Supported Opinions in Medical Journals
Establishes the Total Addressable Market:
Stock Buyback:
A Compelling Opportunity for a Major Pharmaceutical Company
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News